Shigeo Matsuda
Overview
Explore the profile of Shigeo Matsuda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1476
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu M, Qin J, Liu X, Ramsden D, Williams B, Zlatev I, et al.
Nucleic Acids Res
. 2024 May;
52(10):5423-5437.
PMID: 38742636
Oral delivery is the most widely used and convenient route of administration of medicine. However, oral administration of hydrophilic macromolecules is commonly limited by low intestinal permeability and pre-systemic degradation...
2.
Matsuda S, Bala S, Liao J, Datta D, Mikami A, Woods L, et al.
J Am Chem Soc
. 2023 Aug;
145(36):19691-19706.
PMID: 37638886
Chemical modifications are necessary to ensure the metabolic stability and efficacy of oligonucleotide-based therapeutics. Here, we describe analyses of the α-(l)-threofuranosyl nucleic acid (TNA) modification, which has a shorter 3'-2'...
3.
Kandasamy P, Mori S, Matsuda S, Erande N, Datta D, Willoughby J, et al.
J Med Chem
. 2023 Feb;
66(4):2506-2523.
PMID: 36757090
Conjugation of synthetic triantennary -acetyl-d-galactosamine (GalNAc) to small interfering RNA (siRNA) mediates binding to the asialoglycoprotein receptor (ASGPR) on the surface of hepatocytes, facilitating liver-specific uptake and siRNA-mediated gene silencing....
4.
Guenther D, Mori S, Matsuda S, Gilbert J, Willoughby J, Hyde S, et al.
J Am Chem Soc
. 2022 Aug;
144(32):14517-14534.
PMID: 35921401
Although 2'-deoxy-2'-α-F-2'-β--methyl (2'-F/Me) uridine nucleoside derivatives are a successful class of antiviral drugs, this modification had not been studied in oligonucleotides. Herein, we demonstrate the facile synthesis of 2'-F/Me-modified pyrimidine...
5.
Brown K, Nair J, Janas M, Anglero-Rodriguez Y, Dang L, Peng H, et al.
Nat Biotechnol
. 2022 Jun;
40(10):1500-1508.
PMID: 35654979
Therapeutics based on short interfering RNAs (siRNAs) delivered to hepatocytes have been approved, but new delivery solutions are needed to target additional organs. Here we show that conjugation of 2'-O-hexadecyl...
6.
Akabane-Nakata M, Chickering T, Harp J, Schlegel M, Matsuda S, Egli M, et al.
Org Lett
. 2021 Dec;
24(2):525-530.
PMID: 34958225
Toward the goal of evaluation of carbocyclic ribonucleoside-containing oligonucleotide therapeutics, we developed convenient, scalable syntheses of all four carbocyclic ribonucleotide phosphoramidites and the uridine solid-support building block. Crystallographic analysis confirmed...
7.
Schlegel M, Matsuda S, Brown C, Harp J, Barry J, Berman D, et al.
Nucleic Acids Res
. 2021 Oct;
49(19):10851-10867.
PMID: 34648028
We recently reported that RNAi-mediated off-target effects are important drivers of the hepatotoxicity observed for a subset of GalNAc-siRNA conjugates in rodents, and that these findings could be mitigated by...
8.
Jahns H, Taneja N, Willoughby J, Akabane-Nakata M, Brown C, Nguyen T, et al.
Nucleic Acids Res
. 2021 Jul;
50(3):1221-1240.
PMID: 34268578
A critical challenge for the successful development of RNA interference-based therapeutics therapeutics has been the enhancement of their in vivo metabolic stability. In therapeutically relevant, fully chemically modified small interfering...
9.
Akabane-Nakata M, Erande N, Kumar P, Degaonkar R, Gilbert J, Qin J, et al.
Nucleic Acids Res
. 2021 Feb;
49(5):2435-2449.
PMID: 33577685
We recently reported the synthesis of 2'-fluorinated Northern-methanocarbacyclic (2'-F-NMC) nucleotides, which are based on a bicyclo[3.1.0]hexane scaffold. Here, we analyzed RNAi-mediated gene silencing activity in cell culture and demonstrated that...
10.
Mikami A, Erande N, Matsuda S, Kelin A, Woods L, Chickering T, et al.
Nucleic Acids Res
. 2020 Sep;
48(18):10101-10124.
PMID: 32990754
Various chemical modifications have been identified that enhance potency of small interfering RNAs (siRNAs) and that reduce off-target effects, immune stimulation, and toxicities of metabolites of these therapeutic agents. We...